| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/20/2005 | US20050014785 Treatment of radiation disorders |
| 01/20/2005 | US20050014784 Endostatin-like angiogenesis inhibition |
| 01/20/2005 | US20050014783 Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| 01/20/2005 | US20050014782 Novel n-(heterobicycloalkanes)-substituted indoles-or heteroderivatives thereof |
| 01/20/2005 | US20050014781 Ring fused pyrazole derivatives as CRF antagonists |
| 01/20/2005 | US20050014779 Compositions and methods for treatment of neurological disorders |
| 01/20/2005 | US20050014778 Variolin derivatives as anti-cancer agents |
| 01/20/2005 | US20050014777 Antitumor agents; anticancer agents; leukemia; central nervous system; mammary glands; prostate glands; skins |
| 01/20/2005 | US20050014776 Steroidal compounds for inhibiting steroid sulphatase |
| 01/20/2005 | US20050014775 Anticancer agents |
| 01/20/2005 | US20050014774 Oxo-pyrimidine compounds |
| 01/20/2005 | US20050014773 Therapeutic use |
| 01/20/2005 | US20050014772 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 01/20/2005 | US20050014771 fused thienopyrimidine compounds useful as phosphatidylinositol 3-kinase inhibitors and carcinostatic agents |
| 01/20/2005 | US20050014770 Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
| 01/20/2005 | US20050014769 Anticancer agents; controlling apoptosis |
| 01/20/2005 | US20050014768 Antiinflammatory agents; analgesics |
| 01/20/2005 | US20050014767 Controlling cell proliferative |
| 01/20/2005 | US20050014766 Use of n-(indolecarbonyl-)piperazine derivatives |
| 01/20/2005 | US20050014764 Psychological disorders; autism; metal retardation; obsessive compulsive disorders |
| 01/20/2005 | US20050014763 Antiinflammatory agents; antiallergens; respiratory system disorders |
| 01/20/2005 | US20050014762 Combination |
| 01/20/2005 | US20050014759 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis |
| 01/20/2005 | US20050014757 Serotonin receptor antagonist; psychological disorders; side effect reduction |
| 01/20/2005 | US20050014755 Tetracyclic compounds as c-Met inhibitors |
| 01/20/2005 | US20050014754 Anticancer agents; antiinflammatory agents; autoimmune disease |
| 01/20/2005 | US20050014753 Antitumor agents |
| 01/20/2005 | US20050014752 Viricides; anticancer bagents; nucleotides, nucleosides |
| 01/20/2005 | US20050014749 Piperazine derivatives and methods of use |
| 01/20/2005 | US20050014748 N-type calcium channel blockers |
| 01/20/2005 | US20050014746 compounds which bind to the interaction-domain (I-domain) of LFA-1, thus interrupting endothelial cell-leukocyte adhesion by blocking the interaction of LFA-1 with ICAM-1, ICAM-3, and other adhesion molecules |
| 01/20/2005 | US20050014745 Such as 3-[[4-(4-chlorophenyl)-2-thiazolyl]methoxy]-N-propyl-benzenemethanamine; nicotinamide adenine dinucleotide oxidase hydride donor inhibitors |
| 01/20/2005 | US20050014744 Benzothiazine and benzothiadiazine compounds |
| 01/20/2005 | US20050014743 Synergistic mixture; antidepressants; multiple sclerosis; Parkinson's disease; Alzheimer's disease; antitumor agents; sleep disorders; glandular disorders |
| 01/20/2005 | US20050014742 Prevent binding to neuropeptide y; compound containing tertiary amidegroup |
| 01/20/2005 | US20050014741 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 01/20/2005 | US20050014740 E.g. 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or piperazine or hydrochloride or oxalate; treating depression, anxiety, and obsessive compulsive disorders |
| 01/20/2005 | US20050014738 Solid phase extraction; contacting with adsorption resin |
| 01/20/2005 | US20050014737 Antiangiogenic agents |
| 01/20/2005 | US20050014736 Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 01/20/2005 | US20050014735 Therapy for autoimmune disease; antiallergens; antihistamines |
| 01/20/2005 | US20050014734 Stabilization concentration of interleukins; lupus; antiarthritic agents; anticancer agents; antiallergens; skin disorders; aids |
| 01/20/2005 | US20050014732 Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| 01/20/2005 | US20050014731 Treatment of Th1 dominated immunological disease states with non-endogenous gestagen compounds |
| 01/20/2005 | US20050014730 Anti-fungal formulation of triterpene and essential oil |
| 01/20/2005 | US20050014729 Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| 01/20/2005 | US20050014728 Therapy or prevention of diseases caused by lymphocyte interaction; antiinflamamtory agents; autoimmune disease |
| 01/20/2005 | US20050014727 Antiinflammatoy agents; antiallergens; antiproliferative agents; skin disorders; viral disorders; Alzheimer's disease; muscular disorders; antiarthritic agents |
| 01/20/2005 | US20050014726 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
| 01/20/2005 | US20050014725 Immunosuppressant compounds and compositions |
| 01/20/2005 | US20050014724 Immunosuppressant compounds and compositions |
| 01/20/2005 | US20050014722 Process for preparing n-acylated lysophosphatidylcholine and pharmaceutical composition for treatment of metabolic bone disease comprising said compounds |
| 01/20/2005 | US20050014721 reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids |
| 01/20/2005 | US20050014719 Topical applying cyclodextrins; reduction of cholesterol; herpes virus of mouth, genital; forming immunogens |
| 01/20/2005 | US20050014718 Tumor specific oligosaccharide sequences and use thereof |
| 01/20/2005 | US20050014717 Composition and method for viral inhibition |
| 01/20/2005 | US20050014716 Pancreatic cancer treatment |
| 01/20/2005 | US20050014715 Inosine compounds and their use for treating or preventing an inflammation or reperfusion disease |
| 01/20/2005 | US20050014711 Using oligonucleotide antibody |
| 01/20/2005 | US20050014709 Activating using imidazoleacetic acid; receptor moderator signal trabscription; releasing arachidonic acid; hypotensive agents, central nervous system disorders; psychological disorders |
| 01/20/2005 | US20050014706 Method of treating tuberculosis |
| 01/20/2005 | US20050014705 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/20/2005 | US20050014704 Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof |
| 01/20/2005 | US20050014703 Cell differentiation, regeneration of epithelium pancreas cells into insulin producing beta-cells; administrering a peptidyl- peptidase activator |
| 01/20/2005 | US20050014702 Inhibition of pdf enzyme as bactericidal agents for veterinary medicines |
| 01/20/2005 | US20050014701 Synergistic mixture; anticoagulants |
| 01/20/2005 | US20050014700 Cbi analogues of cc-1065 and the duocarmycins |
| 01/20/2005 | US20050014699 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 01/20/2005 | US20050014698 Antioxidat food; polypeptide containing methionine, cysteine |
| 01/20/2005 | US20050014697 Reduce concentration of nitric oxide ; antiinflamamtory agents, stroke, antiproliferative agents; gastrointestinal disorders; inflammatory bowel disorders; antiarthritic agents; Parkinson's disease; Alzheimer's disease;amyotroic lateral sclerosis; anticancer agents |
| 01/20/2005 | US20050014694 to treat inflammatory, non-autoimmune central nervous system (CNS) diseases such as brain tumor, or central nervous system viral or bacterial infection,inhibit the activity of matrix metalloproteinases and suppress cytokine production by T lymphocytes |
| 01/20/2005 | US20050014693 Transmission and, or amplification of signals; oral or enteric administering, dissolving, absorption of peptide yy; obesity therapy |
| 01/20/2005 | US20050014691 Ophthalmic compositions comprising trefoil factor family peptides |
| 01/20/2005 | US20050014690 Styryl acrylonitrile compounds and their use to promote myelopoiesis |
| 01/20/2005 | US20050014688 Inducer of apoptosis |
| 01/20/2005 | US20050014676 Activation of MAPK signal transduction cascade; mitogen-activated protein kinase inhibitor |
| 01/20/2005 | US20050014675 Therapy for vascular system disease; using growth hormonr secretion promoter compound ; artheriosclerosis; cardiovascular disorders; anticholesterol agents |
| 01/20/2005 | US20050014262 Viral expression vector for use as heterologous gene and/or therapeutic protein delivery tools; genetic vaccine |
| 01/20/2005 | US20050014259 Nucleic acid delivery |
| 01/20/2005 | US20050014232 Novel tetronic acid derivative |
| 01/20/2005 | US20050014222 Phosphatases which activate map kinase pathways |
| 01/20/2005 | US20050014187 Novel polypeptide hormone phosphatonin |
| 01/20/2005 | US20050014158 Using presence of polymorphic sequences in gene associated with phospholipase to diagnose, prognose and treat non-insulin dependent diabetes mellitus and obesity |
| 01/20/2005 | US20050013924 Electrostatically depositing active materials as dry powder onto polymer substrate |
| 01/20/2005 | US20050013887 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/20/2005 | US20050013886 Cigarette substitute and aid to quit tobacco use |
| 01/20/2005 | US20050013884 Mixture of protein, phospholipids, vitamins and minerals |
| 01/20/2005 | US20050013881 Topical applying to skins |
| 01/20/2005 | US20050013880 Using plant extracts from grapes, berries as anticancer agents |
| 01/20/2005 | US20050013879 Method for extracting antineoplastic components from Bupleurum scorzonerifolium |
| 01/20/2005 | US20050013875 Immunopotentiators in thermotherapy for cancer |
| 01/20/2005 | US20050013874 Suspension or particle-solvent mixture system of zinc-containing calcium phosphate microparticles and therapeutic agent for treating zinc deficiency |
| 01/20/2005 | US20050013871 Pharmaceutical composition for the treatment of itch |
| 01/20/2005 | US20050013868 Preparation of submicron sized nanoparticles via dispersion lyophilization |
| 01/20/2005 | US20050013867 Use of proton sequestering agents in drug formulations |
| 01/20/2005 | US20050013866 Particulate vectors for improving oral absorption of active principles |
| 01/20/2005 | US20050013862 Functional powders for oral delivery |
| 01/20/2005 | US20050013859 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt |
| 01/20/2005 | US20050013858 Sustained release formulation; shorter treatment duration; higher tolerance; fungal infections |
| 01/20/2005 | US20050013856 Solid dispersions comprising a hygroscopic and/or deliquescent drug |